427 related articles for article (PubMed ID: 30875019)
1. Migalastat: A Review in Fabry Disease.
McCafferty EH; Scott LJ
Drugs; 2019 Apr; 79(5):543-554. PubMed ID: 30875019
[TBL] [Abstract][Full Text] [Related]
2. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
[TBL] [Abstract][Full Text] [Related]
3. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
[TBL] [Abstract][Full Text] [Related]
4. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.
Narita I; Ohashi T; Sakai N; Hamazaki T; Skuban N; Castelli JP; Lagast H; Barth JA
Clin Exp Nephrol; 2020 Feb; 24(2):157-166. PubMed ID: 31889231
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.
Giugliani R; Waldek S; Germain DP; Nicholls K; Bichet DG; Simosky JK; Bragat AC; Castelli JP; Benjamin ER; Boudes PF
Mol Genet Metab; 2013 May; 109(1):86-92. PubMed ID: 23474038
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.
Feldt-Rasmussen U; Hughes D; Sunder-Plassmann G; Shankar S; Nedd K; Olivotto I; Ortiz D; Ohashi T; Hamazaki T; Skuban N; Yu J; Barth JA; Nicholls K
Mol Genet Metab; 2020; 131(1-2):219-228. PubMed ID: 33012654
[TBL] [Abstract][Full Text] [Related]
8. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.
Schiffmann R; Bichet DG; Jovanovic A; Hughes DA; Giugliani R; Feldt-Rasmussen U; Shankar SP; Barisoni L; Colvin RB; Jennette JC; Holdbrook F; Mulberg A; Castelli JP; Skuban N; Barth JA; Nicholls K
Orphanet J Rare Dis; 2018 Apr; 13(1):68. PubMed ID: 29703262
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study.
Germain DP; Nicholls K; Giugliani R; Bichet DG; Hughes DA; Barisoni LM; Colvin RB; Jennette JC; Skuban N; Castelli JP; Benjamin E; Barth JA; Viereck C
Genet Med; 2019 Sep; 21(9):1987-1997. PubMed ID: 30723321
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
Germain DP; Hughes DA; Nicholls K; Bichet DG; Giugliani R; Wilcox WR; Feliciani C; Shankar SP; Ezgu F; Amartino H; Bratkovic D; Feldt-Rasmussen U; Nedd K; Sharaf El Din U; Lourenco CM; Banikazemi M; Charrow J; Dasouki M; Finegold D; Giraldo P; Goker-Alpan O; Longo N; Scott CR; Torra R; Tuffaha A; Jovanovic A; Waldek S; Packman S; Ludington E; Viereck C; Kirk J; Yu J; Benjamin ER; Johnson F; Lockhart DJ; Skuban N; Castelli J; Barth J; Barlow C; Schiffmann R
N Engl J Med; 2016 Aug; 375(6):545-55. PubMed ID: 27509102
[TBL] [Abstract][Full Text] [Related]
11. Assessment of plasma lyso-Gb
Bichet DG; Aerts JM; Auray-Blais C; Maruyama H; Mehta AB; Skuban N; Krusinska E; Schiffmann R
Genet Med; 2021 Jan; 23(1):192-201. PubMed ID: 32994552
[TBL] [Abstract][Full Text] [Related]
12. Migalastat: First Global Approval.
Markham A
Drugs; 2016 Jul; 76(11):1147-52. PubMed ID: 27351440
[TBL] [Abstract][Full Text] [Related]
13. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data.
Riccio E; Zanfardino M; Ferreri L; Santoro C; Cocozza S; Capuano I; Imbriaco M; Feriozzi S; Pisani A;
Eur J Hum Genet; 2020 Dec; 28(12):1662-1668. PubMed ID: 32647377
[TBL] [Abstract][Full Text] [Related]
14. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.
Oommen S; Zhou Y; Meiyappan M; Gurevich A; Qiu Y
Mol Genet Metab; 2019 May; 127(1):74-85. PubMed ID: 31036492
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort.
Nowak A; Huynh-Do U; Krayenbuehl PA; Beuschlein F; Schiffmann R; Barbey F
J Inherit Metab Dis; 2020 Mar; 43(2):326-333. PubMed ID: 31449323
[TBL] [Abstract][Full Text] [Related]
16. Challenges in Fabry disease: the combination of two individually amenable
Fernandes RM; Bento D; Marques N; Azevedo O; Mota T; Costa H; Santo ME; Silva DC; Jesus I
Future Cardiol; 2023 Jan; 19(1):39-43. PubMed ID: 36695159
[TBL] [Abstract][Full Text] [Related]
17. Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year.
Müntze J; Gensler D; Maniuc O; Liu D; Cairns T; Oder D; Hu K; Lorenz K; Frantz S; Wanner C; Nordbeck P
Clin Pharmacol Ther; 2019 May; 105(5):1224-1233. PubMed ID: 30506669
[TBL] [Abstract][Full Text] [Related]
18. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).
Lenders M; Nordbeck P; Kurschat C; Eveslage M; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; von Cossel K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):272-281. PubMed ID: 35512362
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).
Lenders M; Nordbeck P; Kurschat C; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; Stumpfe K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
Clin Pharmacol Ther; 2020 Aug; 108(2):326-337. PubMed ID: 32198894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
